Nitric oxide therapy For cardiovascular disease

Bibliography

• KNOWLES RG, MONCADA S: Nitric oxide synthases in mammals. Biochem.(1994) 298:249–258.
   Web of Science ®Google Scholar
• BRYK R, WOLFF DJ: Pharmacological modulation of nitric oxide synthesis by mechanism-based inactivators and related inhibitors. Pharmacol Therap.(1999) 84:157–178.
   PubMedGoogle Scholar
• FURCHGOTT RF, ZAWADSKI JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature(1980) 228:373–376.
   Web of Science ®Google Scholar
• PALMER RMJ, ASHTON DS, MONCADA S: Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature(1988) 333:664–666.
   PubMed Web of Science ®Google Scholar
• PALMER RMJ, FERRIGE AG, MONCADA S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature(1987) 327:524–526.
   PubMed Web of Science ®Google Scholar
• LAIGHT DW, CARRIER MJ, ÄNGGARD EE: Endothelial cell dysfunction and the pathogenesis of diabetic macroangiopathy. Diabetes Metab. Res. Rev(1999) 15:274–282.
   PubMed Web of Science ®Google Scholar
• DREXLER H, HORNIG B: Endothelial dysfunction in human disease. j Mal Cell Cardiol(1999) 31:51–60.
   PubMed Web of Science ®Google Scholar
• MOMBOULI J-V, VANHOUTTE PM: Endothelial dysfunction: from physiology to therapy. J. Ma. Cell Cardiol(1999) 31:61–74.
   PubMedGoogle Scholar
• REAVEN GM: Role of insulin resistance inhuman disease. Physic] Rev(1995) 75:473–486.
   PubMed Web of Science ®Google Scholar
• GRYGLEWSKI RJ, PALMER RMJ, MONCADA S: Superoxide anion is involved in the breakdown of endothelium-derived relaxing factor. Nature(1986) 320:454–458.
   PubMed Web of Science ®Google Scholar
• M1DNZEL T, HEITZER T, HARRISON DG: The physiology and pathophysiology of the nitric oxide/superoxide system. Herz(1997) 22:158–172.
   PubMedGoogle Scholar
• LAIGHT DW, CARRIER MJ, ÄNGGARD EE: Antioxidants, diabetes and endothelial dysfunction. Cardiovasc. Res.(2000) 47:457–464.
   PubMed Web of Science ®Google Scholar
• ZALBA G, BEAUMONT J, JOSE GS, FORTUNO A, FORTUNO MA, DIEZ J: Vascular oxidant stress: molecular mechanisms and pathophysiological implications. I Physic] Biochem.(2000) 56:57–64.
   PubMed Web of Science ®Google Scholar
• PRITCHARD KA, GROSZEK L, SMALLEY DM et al.:Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ. Res.(1995) 77:510–518.
   PubMed Web of Science ®Google Scholar
• HERBACZYNSKA-CEDRO K: Positive and negative outcomes of L-arginine therapy in cardiovascular diseases. I Physic] Pharmacol(1999) 50:653–660.
   PubMedGoogle Scholar
• BOGER RH, BODE-BOGER SM: Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway and cardiovascular diseases. Sem:in. Thromb. Hemostas.(2000) 26:539–545.
   PubMedGoogle Scholar
• BOGER RH, BODE-BOGER SM, SZUBA A et al.:Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction. Circulation(1998) 98:1842–1847.
   PubMed Web of Science ®Google Scholar
• FUNG H-L, CHONG SJ, BAUER JA, CHING S, KOWALUK EA: Biochemical mechanisms of organic nitrate action. Am. Cardiol(1992) 70:4B–10B.
   Google Scholar
• WEINBERGER B, HECK DE, LASKIN DL, LASKIN JD. Nitric oxide in the lung: therapeutic and cellular mechanisms of action. Pharmacol Therap.(1999) 84:401–411.
   PubMed Web of Science ®Google Scholar
• TUCKER AT, PEARSON RM, COOKE ED, BENJAMIN N: Effects of a nitric oxide generating system on microcirculatory blood flow in skin of patients with severe Raynaud's Syndrome: a randomised trial. Lancet(1999) 354:1670–1675.
   PubMedGoogle Scholar
• MONCADA S: Nitric oxide: discovery and impact on clinical medicine. j Royal Soc. Med.(1999) 92:164–169.
   PubMed Web of Science ®Google Scholar
• MEGSON IL, SOGO N, MAZZEI FA, BUTLER AR, WALTON JC, WEBB DJ: Inhibition of human platelet aggregation by a novel S-nitrosothiol is abolished by haemoglobin and red blood cells in vitro:implications for anti-thrombotic therapy. Br. J. PharmacoL(2000) 131:1391–1398.
   PubMed Web of Science ®Google Scholar
• HOGG N: Biological chemistry and clinical potential of S-nitrosothiols. Free Rad. Biol. Med.(2000) 28:1478–1486.
   PubMed Web of Science ®Google Scholar
• STAMLER JS, JARAKI 0, OSBOURNE J et al.:Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc. Natl. Acad. Li.(1992) 89:7674–7677.
   Google Scholar
• LAIGHT DL, ANDREWS TJ, HAJ-YEHIA Al, CARRIER MJ, ANGGARD EE: Microassay of superoxide anion scavenging activity in vitro. Environ. ToxicoL PharmacoL(1997) 3:65–68.
   PubMedGoogle Scholar
• LANGTRY HD, MARKHAM A: Sildenafil - a review of its use in erectile dysfunction. Drugs(1999) 57:967–989.
   PubMed Web of Science ®Google Scholar
• BIVALACQUA TJ, CHAMPION HC, HELLSTROM WJG, KADOWITZ PJ: Pharmacotherapy for erectile dysfunction. Trends PharmacoL Li.(2000) 21:484–489.
   PubMed Web of Science ®Google Scholar
• JANERO DR: Nitric oxide (NO)-related pharmaceuticals: contemporary approaches to therapeutic NO modulation. Free Rad. Biol. Med.(1999) 28:1495–1506.
   Google Scholar
• DIKALOV S, FINK B, SKATCHKOV M, BASSENGE E: Comparison of glyceryl trinitrate-induced with pentaerythrityl tetranitrate-induced in vivoformation of superoxide radicals: effect of vitamin C. Free Rad. Biol. Med.(1999) 27:170–176.
   PubMedGoogle Scholar
• DIKALOV S, SKATCHKOV M, FINK B, SOMMER D, STALLEICKEN D, BASSENGE E: Formation of reactive oxygen species and nitrate tolerance are caused by all nitrovasodilators except PETN Faseb J.(1997) 11:A60.
   Google Scholar
• CHEN AFY, OBRIEN T, KATUSIC ZS: Transfer and expression of recombinant nitric oxide synthase genes in the cardiovascular system. Trends PharmacoL Sci.(1998) 19:276–286.
   PubMedGoogle Scholar
• YU Q, SHAO R, QIAN HS, GEORGE SF, ROCKEY DC: Gene transfer of the neuronal NOS isoform to cirrhotic rat liver ameliorates portal hypertension. j. Chu. Invest.(2000) 105:741–748.
   PubMed Web of Science ®Google Scholar
• DARIUS H: Role of nitrates for the therapyof coronary artery disease patients in the years beyond 2000. 1 Cardiovasc. PharmacoL(1999) 34 (Suppl. 2): 515–S20.
   Google Scholar
• MONZEL T, SAYEGH H, FREEMAN BA, TARPEY MM, HARRISON DG: Evidence for enhanced vascular superoxide anion production in nitrate tolerance. j. Chu. Invest.(1995) 95:187–194.
   PubMedGoogle Scholar
• SAGE PR, DE LA LANDE IS, STAFFORD I et al.: Nitroglycerin tolerance in human vessels-evidence for impaired nitroglycerin bioconversion. Circulation(2000) 102:2810–2815.
   Google Scholar
• MONZEL T, LI H, MOLLNAU H et al.:Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production and vascular NO bioavailability. Circ. Res.(2000) 86:e7–e12.
   PubMedGoogle Scholar
• ABOU-MOHAMED G, KAESEMEYER WH, CALDWELL RB, CALDWELL RW: Role of L-arginine in the vascular actions and development of tolerance to nitroglycerin. Br. 1 PharmacoL(2000) 130:211–218.
   Google Scholar
• MARIN J, RODRIGUEZ-MARTINEZ MA: Role of vascular nitric oxide in physiological and pathological conditions. PharmacoL Ther.(1997) 75:111–134.
   PubMed Web of Science ®Google Scholar
• KURZ S, HINK U, NICKENIG G, BORTHAYRE AB, HARRISON DG, MONZEL T: Evidence for a causal role of the renin-angiotensin system in nitrate tolerance. Circulation(1999) 99:3181–3187.
   PubMedGoogle Scholar
• MONZEL T, BASSENGE E: Long-term angiotensin-converting enzyme inhibition with high dose enalapril retards nitrate tolerance in large epicardial arteries and prevents rebound coronary vasoconstriction in vivo. Circulation(1996) 93:2052–2058.
   PubMedGoogle Scholar
• BERKENBOOM G, FONTAINE D, UNGER P, BALDASSARRE S, PREIMONT N, FONTAINE J: Absence of nitrate tolerance after long-term treatment with ramipril: an endothelium-dependent mechanism. j. Cardiovasc. PharmacoL(1999) 34:547–553.
   PubMedGoogle Scholar
• WATANABE H, KAKIHANA M, OHTSUKA S, SUGISHITA Y: Effects of enalapril during continuous nitrate therapy: analysis of coronary arteries and platelet c GMT'. Am. Heart J.(1997) 134:614–621.
   PubMedGoogle Scholar
• BASSENGE E, FINK N, SKATCHKOV M, FINK B: Dietary supplementation with vitamin C prevents nitrate tolerance. ..I Chu. Invest.(1998) 102:67–71.
   Google Scholar
• WATANABE H, KAKIHANA M, OHYSUKA S, SUGISHITA Y: Randomised, double-blind, placebo-controlled study of supplemental vitamin E on attenuation of the development of nitrate tolerance. Circulation96: 2545-2550.
   Google Scholar
• MILONE SD, PACE-ASCIAK CR, REYNAUD D, AZEVDO ER, NEWTON GE, PARKER JD: Biochemical, hemodynamic and vascular evidence concerning the free radical hypothesis of nitrate tolerance. ..I Cardiovasc. PharmacoL(1999) 33:685–690.
   PubMedGoogle Scholar
• MILONE SD, AZEVEDO ER, NEWTON GE, FORSTER C, PARKER JD: The angiotensin II-receptor antagonist losartan does not prevent hemodymanic or vascular tolerance to nitroglycerin. 1 Cardiovasc. PharmacoL(1999) 34:645–650.
   PubMedGoogle Scholar
• GLASSER SP: Prospects for therapy of nitrate tolerance. Lancet(1999) 353:1545–1546.
   PubMed Web of Science ®Google Scholar
• NEEDLEMAN P, JOHNSON EM: Mechanisms of tolerance development to organic nitrates. 1 PharmacoL Exp. Therap.(1973) 184:709–715.
   PubMed Web of Science ®Google Scholar
• WATANABE H, NAKAGAWA K, KAKIHANA M: Nitrate therapy during continuous nitrate therapy in patients with ischaemic heart disease. Circulation(1999) 100\(Suppl. 5):186–187.
   Google Scholar
• MCVEIGH GE, BENNAN GM, HAYES R, JOHNSTON GD: Primary nitrate tolerance in diabetes mellitus. Diabetoiogia(1994) 37:115–117.
   PubMed Web of Science ®Google Scholar
• CHIRKOV YY, HOLMES AS, CHIRKOVA LP, HOROWITZ J: Nitrate resistance in platelets from patients with stable angina pectoris. Circulation(1999) 100:129–134.
   PubMedGoogle Scholar
• LAIGHT DW, ANDREWS TJ, HAJ-YEHIA Al, CARRIER MJ, ANGGARD EE: Investigation of oxidant stress and vasodepression to glyceryl trinitrate in the obese Zucker rat in vivo. Br. j. PharmacoL(1998) 125:895–901.
   PubMed Web of Science ®Google Scholar
• DARLEY-USMAR V, HOGG N, KALYANARAMAN B, MOORE K: Free radicals in the vasculature: pathological and physiological significance. In: OxidativeStress, lipoproteins and cardiovascular dysfunction.Rice-Evans C, Bruckdorfer KR (Eds.), Portland Press Ltd, London, UK (1995): 81–99.
   Google Scholar
• DUFFY SJ, GOKCE N, HOLBROOK M et al.:Treatment of hypertension with ascorbic acid. Lancet(1999) 354:2048–2049.
   PubMed Web of Science ®Google Scholar
• BOGER, RH, SYDOW K, BORLAK J et al.:LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells-Involvement of S-adenosylmethionine-dependent methyltransferases. Circ. Res.(2000) 87:99–105.
   PubMed Web of Science ®Google Scholar
• MARCHIOLI R: Antioxidant vitamins and prevention of cardiovascular disease: laboratory, epidemiological and clinical trial data. Pharmacol Res.(1999) 40:227–238.
   PubMed Web of Science ®Google Scholar
• BULT H, HERMAN AG, MATTHYS KE: Antiathersclerotic activity of drugs in relation to NO function. Eur. j Pharmacol(1999) 375:157–176.
   PubMed Web of Science ®Google Scholar
• BROEDERS MA, DOEVENDANS PA, BEKKERS BC et al.:Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production. Circulation(2000) 102:677–684.
   PubMed Web of Science ®Google Scholar
• MOMBOULI J-V: ACE inhibition, endothelial function and coronary artery lesions. Role of kinins and nitric oxide. Drugs(1997) 54:S5 12–22.
   Google Scholar
• BANDOH T, MITANI H, NIIHASHI M et al.:Fluvastatin suppresses atherosclerotic progression, mediated through its inhibitory effect on endothelium dysfunction, lipid peroxidation and macrophage deposition. Cardiovasc. Pharmacy].(2000) 35:136–144.
   PubMedGoogle Scholar
• JOHN S, JACOBI J, DELLES C, SCHLAICH ME SNEIDER M, SCHMIEDER R: Rapid improvement of endothelial function after lipid-lowering therapy within 2 weeks. Am. Coll. Cardiol(2000) 35:256A.
   Google Scholar
• Developments with nitric oxide drugs. Pharm. J.(2000) 264:431.
   Google Scholar